⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55714 | 0.81 | — | — | |
| SCHEMBL2139141 | 0.73 | — | — | |
| SCHEMBL972246 | 0.59 | — | — | |
| SCHEMBL2439739 | 0.59 | — | — | |
| SCHEMBL23030281 | 0.56 | — | — | |
| SCHEMBL18695288 | 0.56 | CYP2C9 (0.32) | — | |
| SCHEMBL2142701 | 0.56 | — | — | |
| SCHEMBL23916928 | 0.56 | — | — | |
| SCHEMBL16878021 | 0.56 | — | — | |
| SCHEMBL9675320 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416248-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-12-28 | — | — | US | claimed |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-16 | — | — | US | claimed |
| EP-4244213-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| WO-2022103899-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-19 | — | — | WO | claimed |
| WO-2019063704-A1 | SUBSTITUTED 3-PHENYLQUINAZOLIN-4(3H)-ONES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-04-04 | — | — | WO | claimed |
| WO-2019063708-A1 | SUBSTITUTED 3-PHENYLQUINAZOLIN-4(3H)-ONES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-04-04 | — | — | WO | claimed |
| US-20230416248-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230365560-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| EP-4244213-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022103899-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3538512-B1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2021-06-16 | — | — | EP | disclosed |
| US-20210115026-A1 | NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-10889573-B2 | Anthelmintic quinoline-3-carboxamide derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-01-12 | — | — | US | disclosed |
| WO-2008032064-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032072-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032036-A1 | 6-BENZIMIDAZ0LYL-2-M0RPH0LIN0-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032086-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032041-A1 | PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST PI3K ENZYMES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032089-A1 | 4-BENZIMIDAZ0LYL-2-M0RPH0LIN0-6-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032033-A1 | 4-BENZIMIDAZOLYL-2-MORPHOLINO-6-PIPERAZINYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |